NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Clinical and Laboratory Analysis of Familial Cancer

Completed

Conditions: Cancer

First Posted Date: 2015-10-01

Last Posted Date: 2022-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT02565004

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Follow-Up Study of People Treated for Scoliosis

Completed

Conditions: Respiratory Disease Mortality
Circulatory Disease Mortality
Breast and Other Cancer Incidence and Mortality
All Cause Mortality

First Posted Date: 2015-09-11

Last Posted Date: 2019-07-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5573

Registration Number: NCT02546479

Locations: 🇺🇸
National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, United States

Quantifying the Persistence of Metabolic Adaptation and Weight Regain Following Extreme Weight Loss

Completed

Conditions: Energy Expenditure

First Posted Date: 2015-09-09

Last Posted Date: 2025-04-22

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 15

Registration Number: NCT02544009

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

Recruiting

Conditions: Plexiform Neurofibromas
Neurofibromatosis 1

First Posted Date: 2015-09-09

Last Posted Date: 2025-06-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 486

Registration Number: NCT02544022

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Cincinnati Children's Hospital and Medical Center Institution, Cincinnati, Ohio, United States

and more 3 locations

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Stage IV Lung Large Cell Carcinoma AJCC v7
Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Large Cell Carcinoma AJCC v7
Stage IV Lung Adenocarcinoma AJCC v7
Stage III Lung Adenocarcinoma AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7
Stage III Lung Large Cell Carcinoma AJCC v7
Stage IIIA Lung Adenocarcinoma AJCC v7

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Cisplatin
Radiation: Intensity-Modulated Radiation Therapy
Drug: Methoxyamine
Drug: Methoxyamine Hydrochloride
Drug: Pemetrexed
Drug: Pemetrexed Disodium

First Posted Date: 2015-08-28

Last Posted Date: 2022-06-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT02535325

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Phase 1

Active, not recruiting

Conditions: Recurrent Pleural Malignant Mesothelioma
Unresectable Solid Neoplasm
Refractory Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
Advanced Peritoneal Malignant Mesothelioma
Advanced Pleural Malignant Mesothelioma
Recurrent Peritoneal Malignant Mesothelioma

Interventions: Drug: Methoxyamine
Drug: Cisplatin
Drug: Pemetrexed Disodium

First Posted Date: 2015-08-28

Last Posted Date: 2025-04-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT02535312

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Keck Medical Center of USC Pasadena, Pasadena, California, United States

and more 11 locations

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions: Drug: Erlotinib Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Onalespib Lactate
Other: Pharmacological Study

First Posted Date: 2015-08-28

Last Posted Date: 2025-03-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT02535338

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 3 locations

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

Phase 2

Active, not recruiting

Conditions: Barrett Esophagus
Esophageal Adenocarcinoma

Interventions: Drug: Aspirin
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Other: Questionnaire Administration

First Posted Date: 2015-08-13

Last Posted Date: 2025-03-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT02521285

Locations: 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇨🇦
Saint Michael's Hospital, Toronto, Ontario, Canada
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

and more 7 locations

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
Recurrent Grade 3a Follicular Lymphoma
Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Refractory Grade 2 Follicular Lymphoma
Refractory Grade 3a Follicular Lymphoma
Stage II Mycosis Fungoides AJCC v7
Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma
Stage III Mycosis Fungoides AJCC v7
Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Stage IV Mycosis Fungoides AJCC v7

Interventions: Biological: Anti-ICOS Monoclonal Antibody MEDI-570
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2015-08-13

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT02520791

Locations: 🇺🇸
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 20 locations

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7

Interventions: Drug: Navitoclax
Drug: Osimertinib

First Posted Date: 2015-08-13

Last Posted Date: 2024-08-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT02520778

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 15 locations

Home Terms & Conditions Privacy Policy